Gut MicrobesBiochemistryPeer-reviewed journal article
Human gut commensal Alistipes timonensis modulates the host lipidome and delivers anti-inflammatory outer membrane vesicles to suppress colitis in an Il10-deficient mouse model
Ethan A. OlderiD, Mary K. MitchelliD, Andrew Campbell, Xiaoying Lian, Michael Madden, Yuzhen WangiD, Lauren E. van de Wal, Thelma Zaw, Brandon N. VanderVeeniD, Rodney Tatum, E. Angela MurphyiD, Yan-Hua Chen, Daping FaniD, Melissa EllermanniD, Jie LiiD
Abstract
Correlative studies have linked human gut microbes to specific health conditions. Alistipes is one such microbial genus negatively linked to inflammatory bowel disease (IBD). However, the protective role of Alistipes in IBD is understudied, and the underlying molecular mechanisms remain unknown. In this study, colonization of Il10-deficient mice with Alistipes timonensis DSM 27924 delays colitis development. Colonization does not significantly alter the gut microbiome composition, but instead shifts the host plasma lipidome, increasing phosphatidic acids while decreasing triglycerides. Outer membrane vesicles (OMVs) derived from Alistipes are detected in the plasma of colonized mice, carrying potentially immunomodulatory metabolites into the host circulatory system. Fractions of A. timonensis OMVs suppress LPS-induced Il6, Il1b, and Tnfa expression in vitro in murine macrophages. We detect putative bioactive lipids in the OMVs, including immunomodulatory sulfonolipids (SoLs) in the active fraction, which are also increased in the blood of colonized mice. Treating Il10-deficient mice with purified SoL B, a representative SoL, suppresses colitis development, suggesting its contribution to the anti-inflammatory phenotype observed with A. timonensis colonization. Thus, A. timonensis OMVs represent a potential mechanism for Alistipes-mediated delay of colitis in Il10-deficient mice via delivery of immunomodulatory lipids and modulation of the host plasma lipidome.
- organism: mouse
- assay: proteomics
- assay: metagenomics
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 40
- FWCI
- 11.00
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Bacterial Sphingolipids Exacerbate Colitis by Inhibiting ILC3-derived IL-22 Production.
B. Bao, Y. Wang, … S. Snapper·bioRxiv·Sep 5, 2023
- Microbial-associated acylated putrescines as immunomodulatory molecules in inflammatory bowel diseases
Sena Bae, Julián Ávila-Pacheco, … Wendy S. Garrett·bioRxiv·Aug 25, 2026
- Miltefosine attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice.
C. A. Traughber, A. J. Iacano, … K. Gulshan·bioRxiv·Aug 22, 2022
- A gut commensal protozoa remotely shapes a lung niche for asthma-promoting eosinophils.
K. Burrows, L. Ngai, … A. Mortha·bioRxiv·Mar 25, 2022
- Gut microbiota phospholipids regulate intestinal gene expression and can counteract the effects of antibiotic treatment
Xue‐Song Zhang, Yujue Wang, … Martin J. Blaser·bioRxiv·Jan 28, 2025
- Early-life microbial intervention reduces colitis risk promoted by antibiotic-induced gut dysbiosis
J. Miyoshi, S. Miyoshi, … E. B. Chang·GastroenterologyPeer-reviewed·Sep 1, 2021